gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

CONKO-101: Erste Ergebnisse einer offenen Phase II Studie mit Gemcitabin, 5-FU (24h), Folinsäure und Cisplatin bei Patienten mit inoperablem Ösophaguskarzinom

Meeting Abstract

  • corresponding author presenting/speaker Jens Stieler - Charité Universitätsmedizin Berlin Campus Virchow Klinikum, Innere Klinik mit Schwerpunkt Hämatologie/Onkologie, Deutschland
  • Andreas Hilbig - Charité Universitätsmedizin Berlin Campus Virchow Klinikum, Innere Klinik mit Schwerpunkt Hämatologie/Onkologie
  • Uwe Pelzer - Charité Universitätsmedizin Berlin Campus Virchow Klinikum, Innere Klinik mit Schwerpunkt Hämatologie/Onkologie
  • Lars Roll - Charité Universitätsmedizin Berlin Campus Virchow Klinikum, Innere Klinik mit Schwerpunkt Hämatologie/Onkologie
  • Bernd Dörken - Charité Universitätsmedizin Berlin Campus Virchow Klinikum, Innere Klinik mit Schwerpunkt Hämatologie/Onkologie
  • Hanno Riess - Charité Universitätsmedizin Berlin Campus Virchow Klinikum, Innere Klinik mit Schwerpunkt Hämatologie/Onkologie
  • Helmut Oettle - Charité Universitätsmedizin Berlin Campus Virchow Klinikum, Innere Klinik mit Schwerpunkt Hämatologie/Onkologie

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO213

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dkk2006/06dkk323.shtml

Published: March 20, 2006

© 2006 Stieler et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Introduction: Standard therapy for inoperable esophageal cancer is a combination of cisplatin and 5-FU combined with radiation for locally advanced stages. As gemcitabine shows synergy with cisplatin and 5-FU, we evaluated the combination of cisplatin 30 mg/m2 (90 min), Gemcitabine 1000 mg/m2 (30 min), FS 200 mg/m2 (30 min) and 5-FU 750 mg/m2 24h CI) d1,8 q d22 for patients with inoperable esophageal cancer. For locally advanced stages, patients received sequential radiochemotherapy with 5-FU CI afterwards.

Patients: 89 (75m/14w)pts. were included into this multicentrical phase 2 study. 58 had SCC, 30 AC, 1 undifferentiated carcinoma. Median age was 61(22-86) years, Median KI 90 (60-100) %. 2 pts. had stage IIa, 4 stage IIb, 30 stage III, 16 stage IVa and 37 stage IVb.

Results: 67 pts. are so far evaluable for response and 84 (according to 410 cycles of therapy) for toxicity. 1 Pt. had pathologically confirmed CR (1,5%), 21 had PR (31,3%), 33 SD (49,2%) and 13 PD (18%) as best response. MS was 10,68 months (13,07 for stage II/III and 9,07 for stage IV). Median TTP was 6 months, and PFS was 5,96 months. Observed toxicity was low and predominantly hematologic with Leukopenia WHO Grade ¾ in 10% of cycles, Hb grade ¾ in 5,3% of cycles and Thrombopenia grade ¾ in 2,4% of cycles.

Conclusion: This regimen is well tolerable and can easily be applied on an outpatient basis, but the remission rates and survival data are within the range previously reported for Cisplatin/5-FU alone.